Filing Flows › Sight Sciences (SGHT) › Q1 2026
Sight Sciences (SGHT) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 6, 2026
Sight Sciences (SGHT) reported revenue of $19.7M for the first quarter 2026 (Q1 2026), +13% from a year earlier and -3% from the quarter before. Operating margin was -63.0%, net loss $13.0M (65.9% of revenue).
Sight Sciences, Q1 2026: revenue $19.7M (+12% year over year), operating margin -63.0%, net loss $13.0M, operating cash flow −$7.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $19.7M | -3% | +13% |
| Operating profit | −$12.4M | — | — |
| Net earnings | −$13.0M | — | — |
| Operating cash flow | −$7.0M | — | — |
What changed
Revenue was $19.7M in Q1 2026, up 13% year over year and down 3% from the previous quarter. Surgical Glaucoma was the largest line at 93% of revenue. Surgical Glaucoma added $1.2M year over year (up 7%), 56% of the total change.
Gross margin was 86.2%, unchanged from Q1 2025. Operating costs exceeded revenue by $12.4M, an operating margin of -63.0%. Operating expenses grew 2% against revenue growth of 13%. The quarter ended with a net loss of $13.0M, wider than the previous quarter's $4.2M loss.
Operating cash flow was −$7.0M. Non-cash charges added back $103K of depreciation and amortization and $2.9M of share-based compensation. Working capital and other items added $3.0M. Capital expenditures of $60K exceeded it, leaving free cash flow of −$7.1M.
Questions
What was Sight Sciences' revenue in the first quarter 2026?
Sight Sciences (SGHT) reported revenue of $19.7M for the first quarter 2026 (Q1 2026), +13% from a year earlier and -3% from the quarter before.
Was Sight Sciences profitable in the first quarter 2026?
Operating loss was $12.4M (-63.0% of revenue) and net loss $13.0M.
Source: Sight Sciences 10-Q on SEC EDGAR.